Search Results

, leptin signaling, and inflammation-linked GPCRs — and curated roles in computational and membrane protein – Assay Volume Control in GPCR Drug Discovery This week in Terry’s Corner, you’ll learn how dialing receptor expression/coupling up or down reveals hidden partial agonism, “silent” agonism, inverse agonism, and Your membership gives you:   Proven   frameworks  for real-world GPCR drug discovery Flexible , on-demand

However, there is a notable lack of fluorescent probes available in the market for this receptor. unlock the therapeutic potential of this important receptor. Function, Structure and Therapeutic Potential of Complement C5a Receptors. S.; Majellaro, M.; Sotelo, E.; Navarro, G.; Franco, R. Orthosteric and Allosteric Action of the C5a Receptor Antagonists.

While experimentalists struggled for months with crystallography, he could pull a clean protein structure from the Protein Data Bank in a single afternoon and move on. For receptor assays and the biological interpretation of ligands, he relies on a network of collaborators Structural biologists may capture snapshots of receptor conformations, but lack large-scale screening

discovery This Week’s GPCR Intelligence: Every drug you design will meet an enzyme before it meets its receptor Enzyme Inhibition Shapes Every Discovery Program Every molecule meets an enzyme before it ever meets its receptor Suntans, and GPCR Micro-Domains Two recent papers connect ciliary signaling, opsins, and melanocortin receptors in appetite circuits and MCR1 in melanocytes highlights the power of localized cAMP and ion channel coupling Localized cAMP and channel coupling as levers for phenotype. New tools, new questions.  

Breakthroughs this week:  Why Everyone’s Talking About Metabolic GPCRs; GPS for proteins: Tracking the motions of cell receptors; A Better Way to Treat Obesity; Unlocking the pharmacological potential of Industry insights:  Metabolic GPCRs climbing the spotlight; new tools tracking receptor motion; obesity Must-read publications:  A structural modeling study revealing non-canonical mechanisms of chemokine-driven receptor This is where the real conversations begin—made possible with the support of NIS, Proteos, and Axxam  

Insights That Prevent Real Drug Discovery Failures Discovery collapses when teams assume stable, linear, receptor-to-response ’s AMA made the central point unmistakable: GPCR systems constantly reshape ligand behavior through coupling efficiency, receptor density, local signaling architecture, and physiological feedback loops. Johannes Broichhagen Reliable imaging tools change how researchers see receptor behavior. antibodies fail How parallel synthesis& testing accelerates probe optimization How surface-exposed receptor

Passive diffusion dominates for many small molecules, but protein binding, transporters, and tissue architecture vivo correlation depends on scaling assumptions and controls CYP inhibition, transporter assays, protein Even perfect receptor pharmacology fails if target-site exposure is insufficient or transient .

Here, we show that the gut IEL GLP-1 receptor (GLP-1R) is not required for enteroendocrine L cell GLP mediated by the suppression of gut IEL effector functions linked to the dampening of proximal T cell receptor signaling in a protein-kinase-A-dependent manner.

The surface expression of pattern recognition receptors, such as TLR2 and TLR4, provides platelets with Platelet α-granules contain microbicidal proteins, chemokines and growth factors, which upon release is characterized by neutrophils expelling chromatin fibres decorated with histones and antimicrobial proteins The negatively charged DNA within NETs provides a procoagulant surface, and in particular NET-derived proteins

Gáspár Pándy-Szekeres ) will present and demonstrate the newest resources of the GPCRdb: 1) the new G protein resources and 2) the structural analysis platform.

Functional assays for GPCRs—especially Gq-coupled receptors—were notoriously messy. Calcium flux? By covalently attaching the probe to FLAG-tagged receptors or using labeled antibodies, they created Their “aha” moment came when they ran a dose-response with Exendin-4 on GLP-1 receptors—and saw clean It reflects decades of foundational R&D—from the fluorescent probes of Cisbio’s early days to the receptor-targeting

Breakthroughs this week: Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling; Proximity-Dependent Proteomics Upcoming events:  Get details on the "neuroGPCR" symposium focusing on receptor signaling and a platform , a case for functionally Gs protein-selective GPCRs, and new methods for detecting simultaneous ligand down with Alessandro Nicoli, from the Technical University of Munich, to discuss his work on olfactory receptors Discover how breakthroughs like AlphaFold are making previously "undruggable" targets, like olfactory receptors

Somatostatin receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent The cytoskeletal protein filamin A (FLNA) directly interacts with both somatostatin receptor type 2 ( octreotide or pasireotide may play modulatory effects and whether FLNA may participate to this level of receptor On the contrary, in M2 cells, octreotide failed to internalize both receptors whereas pasireotide promoted robust receptor internalization at shorter times than in A7 cells.

tissues like tumors slows offset and improves therapeutic window ✅ Examples of how rebinding in dense receptor Diffusion, Rebinding, and Receptor Density: The In Vivo Edge This lecture shows how tissue architecture And when receptors are dense (like GPCRs on membranes), this rebinding hits the collisional limit , where Subscribe to The Kenakin Brief today ➤ #TargetResidenceTime #DrugBindingKinetics #PKPDdissociation #ReceptorPharmacology

September 2022 "The Smoothened receptor (SMO, a 7 pass transmembrane domain, Class F GPCR family protein In the absence of HH signaling, SMO is inhibited by Patched 1 (PTC1; a 12 pass transmembrane domain protein

September 2022 "In the Wnt-β-catenin pathway, Wnt binding to Frizzled (Fzd) and LRP5 or LRP6 (LRP5/6) co-receptors Using purified Fzd proteins reconstituted in lipid nanodiscs, we investigated the factors that promote

Could they map receptor heterogeneity across the islet? Could they quantify plasma membrane vs. intracellular receptor pools? The tools didn’t simply visualize receptors. mapping Super-resolution imaging of receptor nanodomains AI-assisted probe design Multi-receptor visualization Not one receptor at a time. Not one color. Not one imaging depth.

GPCR Activation and Signaling The GPCR adaptor protein Norbin regulates S1PR1 trafficking and the morphology , cell cycle and survival of PC12 cells GLP-1 and GIP receptors signal through distinct β-arrestin 2- mobilization when combined with propranolol Discovery of 3-Phenyl Indazole-Based Novel Chemokine-like Receptor

The cannabinoid receptor type 2 (CB2R) has emerged as a compelling target across inflammation, immune Subcellular membrane mixtures, altered receptor conformations, and non-specific interactions introduce By quantifying ligand–receptor interactions directly in intact cells, HCS allows researchers to observe In a recent collaborative study, 16 synthetic cannabinoid receptor agonists (SCRAs) were evaluated using Because imaging is captured across thousands of intact cells, each measurement incorporates receptor

Screening Compounds are systematically challenged in vitro against a spectrum of cellular targets—enzymes, receptors safety Reactive Metabolites and Irreversible Damage Formation of reactive metabolites that alkylate proteins

Watch Episode 167 Some GPCR-targeting antibodies don’t inhibit receptors. They activate them. Tom Sakmar points to a largely overlooked mechanism  in disease: autoantibodies that don’t block receptors “Some of these antibodies actually activate the receptor and cause pathological signaling.” — Tom Sakmar Luminex assay , researchers can now: Screen patient samples for GPCR autoantibodies Identify which receptor

drugs fail—not because of poor chemistry, but because we’ve misunderstood how these shape-shifting proteins

Kunitz-type snake toxin family associated with an original mode of interaction with the vasopressin 2 receptor from the Dendroaspis angusticeps venom is the most selective antagonist of the arginine-vasopressin V2 receptor

The goal is to accelerate receptor-targeted discovery. It highlights its journey from one receptor to a cross-family toolkit. Hear from Drs. GPR45 steps up: A previously orphan receptor emerges as a powerful target for appetite and obesity control

Think a drug just "locks into" a receptor and does its job? Think again. It explains how the concentration of a drug influences its binding to the receptor. Instead, it involves a dynamic interaction between the drug and the receptor. The receptor may change shape upon binding, affecting how the drug interacts and how effective it will Understanding the intricate details of drug-receptor interactions transforms how we approach pharmacology

Most drugs don’t fail at the receptor level—they fail before they even reach it. In every lab, candidates fail not because they lack potency at a receptor, but because they stumble at Even the most elegant GPCR ligand can fail if it never reaches its receptor. You’re not just designing for receptor activity—you’re designing for enzyme survival. Pharmacology isn’t just about hitting the receptor—it’s about surviving the enzymes first.

Picture this: two compounds bind to the same receptor. One sparks a firestorm of cellular activity. Terry walks you through real-world experiments, decades of receptor pharmacology wisdom, and the cutting-edge

Celtarys Research expands its assay tools with CELT-419 for D3 receptor studies, and Dr. Terry Kenakin brings translational clarity to complex receptor concepts.   Platforms   Celtarys Research presents CELT-419, a nanomolar-affinity fluorescent ligand optimized for D3 receptor Highlights     Phosphorylation selectively regulates β-arrestin recruitment  across glucagon family receptors

University of Michigan, walks us through how positive allosteric modulators (PAMs) targeting the mu-opioid receptor That’s huge.” – Ben Clements By combining chronic pain models with receptor-level pharmacology, Ben Allosteric modulation is already proven in ion channels (think benzodiazepines and barbiturates) but University today. _______________ Keyword Cloud: GPCR research community, GPCR drug discovery, mu-opioid receptor

Fast-forward a few thousand years, and we’re talking beta receptors, receptor theory, and AI-generated